BIO Submits Comments to CMS Regarding its Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Proposed FY 2015 Rates Proposed Rule
<p align="left">
June 30, 2014</p>
<p>
</p>
<p>
<strong><em>BY ELECTRONIC DELIVERY</em></strong></p>
<p>
</p>
<p>
The Honorable Marilyn B. Tavenner</p>
<p>
Administrator</p>
<p>
Centers for Medicare & Medicaid Services</p>
<p>
U.S. Department of Health and Human Services</p>
<p>
Hubert H. Humphrey Building, Room 445-G</p>
<p>
200 Independence Avenue, SW</p>
<p>
Washington, DC 20201</p>
<p>
</p>
<p>
<strong>Re: </strong><strong>Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long Term Care Hospital Prospective Payment System and Proposed Fiscal Year 2015 Rates; Quality Reporting Requirements for Specific Providers; Reasonable Compensation Equivalents for Physician Services in Excluded Teaching Hospitals; Provider Administrative Appeals and Judicial Review; Enforcement Provisions for Organ Transplant Centers; and Electronic Health Record (EHR) Incentive Program; Proposed Rule [CMS-1607-P]</strong></p>
<p>
</p>
<p>
Dear Administrator Tavenner:</p>
<p>
</p>
<p>
The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Centers for Medicare and Medicaid Services’ (CMS’s) Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Proposed Fiscal Year 2015 Rates Proposed Rule (“the Proposed Rule”), specifically with respect to the Hospital Inpatient Quality Reporting (IQR) Program and the Hospital Value-Based Purchasing (VBP) Program.<a href="#_ftn1" name="_ftnref1" title="">[1]</a> BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products. </p>
<div>
<br clear="all" />
<hr align="left" size="1" width="33%" />
<div id="ftn1">
<p>
<a href="#_ftnref1" name="_ftn1" title="">[1]</a> 79 Fed. Reg. 27,978 (May 15, 2014).</p>
</div>
</div>
<p>
</p>
June 30, 2014
BY ELECTRONIC DELIVERY
The Honorable Marilyn B. Tavenner
Administrator
Centers for Medicare & Medicaid Services
U.S. Department of Health and Human Services
Hubert H. Humphrey Building, Room 445-G
200 Independence Avenue, SW
Washington, DC 20201
Re: Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long Term Care Hospital Prospective Payment System and Proposed Fiscal Year 2015 Rates; Quality Reporting Requirements for Specific Providers; Reasonable Compensation Equivalents for Physician Services in Excluded Teaching Hospitals; Provider Administrative Appeals and Judicial Review; Enforcement Provisions for Organ Transplant Centers; and Electronic Health Record (EHR) Incentive Program; Proposed Rule [CMS-1607-P]
Dear Administrator Tavenner:
The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Centers for Medicare and Medicaid Services’ (CMS’s) Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Proposed Fiscal Year 2015 Rates Proposed Rule (“the Proposed Rule”), specifically with respect to the Hospital Inpatient Quality Reporting (IQR) Program and the Hospital Value-Based Purchasing (VBP) Program.[1] BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products.